Internship

Business Development Intern

Posted on 12/20/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Requires in-person commitment for a 10-week full-time summer program in San Diego, CA.

Category
Business Development
Business & Strategy
Required Skills
Market Research
Requirements
  • Third-year undergraduate student with major in the life sciences (Neuroscience major preferred)
  • Market research experience and finance / valuation skills would be an asset but is not required
  • Prior experience in the pharmaceutical or biotechnology industry would be an asset but is not required
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is desirable
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Interest in attending various program events, including social gatherings, career development workshops, and more
  • Ability to commit to a 10-week full-time summer program (in-person in San Diego, CA)
Responsibilities
  • Supporting a range of activities, including deal sourcing as well as product and technology assessment
  • Monitoring industry trends, companies, technologies and therapeutic areas of relevance to Neurocrine
  • Interacting with multiple functional areas within the company such as research, clinical development, and finance
  • Completing a special project and presenting the recommendations to senior management upon completion
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY opens a new market for CAH treatment.
  • Positive Phase 2 data for NBI-1117568 shows promise in schizophrenia treatment.
  • Significant investments from Aigen and Mediolanum indicate strong investor confidence.

What critics are saying

  • Increased competition in CAH treatment may challenge CRENESSITY's market position.
  • Potential strategic shifts with new CEO Kyle Gano could impact company direction.
  • Reliance on FDA approvals poses risks if delays or rejections occur.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first new CAH treatment in 70 years.
  • Neurocrine's INGREZZA sprinkle formulation addresses dysphagia in patients with Huntington's disease.
  • Neurocrine is recognized as a top workplace in biopharma, ranking No. 7 in 2024.

Help us improve and share your feedback! Did you find this helpful?